Actively Recruiting
Long-term Study of HSK39297 Treatment Safety and Effectiveness in Adults With Paroxysmal Nocturnal Hemoglobinuria
Led by Haisco Pharmaceutical Group Co., Ltd. · Updated on 2024-12-20
47
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the long-term safety, tolerability, and effectiveness of HSK39297 in adults with Paroxysmal Nocturnal Hemoglobinuria PNH who have previously completed treatment with HSK39297. The study is multicenter and open-label, focusing on understanding how patients respond to continued treatment over an extended period. The sponsor leading this study is Haisco Pharmaceutical Group Co., Ltd. Participants will continue taking HSK39297 tablets until the end of the study treatment period. There are no placebo or comparator groups, as all eligible participants are those who have already received the study drug. The treatment will be maintained throughout the study to monitor long-term effects. Throughout the study, patients will be monitored for adverse events to assess safety and tolerability over about two years. Researchers will also measure hemoglobin levels, the need for red blood cell transfusions, rates of breakthrough hemolysis, and incidence of major adverse vascular events. Participants will be followed closely to evaluate these outcomes and ensure ongoing safety.
CONDITIONS
Brief Title
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Research Team
L
Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here